Roivant Sciences Ltd. (ROIV) stock
ROIVNasdaqPharmaceutical PreparationsFiscal year ends March 31
$38.73+0.02 (+0.05%)
Close on Nov 18, 2026Market cap $27.98BP/E –Yield –
Roivant Sciences operating income
Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.
Roivant Sciences's operating income for the twelve months ending Jun 30, 2026 was -$596.14M. For fiscal 2025 it was -$515.07M. The highest annual figure on record is $4.50B in fiscal 2023.
Annual operating income
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Mar 31, 2026 | -$515.07M | – |
| FY2024 | Mar 31, 2025 | -$1.00B | -122.3% |
| FY2023 | Mar 31, 2024 | $4.50B | – |
| FY2022 | Mar 31, 2023 | -$906.76M | – |
| FY2021 | Mar 31, 2022 | -$1.35B | – |
| FY2020 | Mar 31, 2021 | -$1.07B | – |
Quarterly operating income
Change is against the same quarter a year earlier.
Periods
| Period | Period end | Value | Change |
|---|---|---|---|
| Q1 FY2026CQ2 2026 | Jun 30, 2026 | -$365.99M | – |
| Q4 FY2025CQ1 2026 | Mar 31, 2026 | $415.24M | – |
| Q3 FY2025CQ4 2025 | Dec 31, 2025 | -$339.15M | – |
| Q2 FY2025CQ3 2025 | Sep 30, 2025 | -$306.23M | – |
| Q1 FY2025CQ2 2025 | Jun 30, 2025 | -$284.92M | – |
| Q4 FY2024CQ1 2025 | Mar 31, 2025 | -$284.97M | – |
| Q3 FY2024CQ4 2024 | Dec 31, 2024 | -$274.38M | -105.4% |
| Q2 FY2024CQ3 2024 | Sep 30, 2024 | -$341.71M | – |
| Q1 FY2024CQ2 2024 | Jun 30, 2024 | -$102.24M | – |
| Q4 FY2023CQ1 2024 | Mar 31, 2024 | -$206.83M | -701.5% |
| Q3 FY2023CQ4 2023 | Dec 31, 2023 | $5.13B | – |
| Q2 FY2023CQ3 2023 | Sep 30, 2023 | -$213.89M | – |
| Q1 FY2023CQ2 2023 | Jun 30, 2023 | -$276.41M | – |
| Q4 FY2022CQ1 2023 | Mar 31, 2023 | $34.39M | – |
| Q3 FY2022CQ4 2022 | Dec 31, 2022 | -$378.08M | – |
| Q2 FY2022CQ3 2022 | Sep 30, 2022 | -$280.77M | – |
| Q1 FY2022CQ2 2022 | Jun 30, 2022 | -$282.31M | – |
| Q4 FY2021CQ1 2022 | Mar 31, 2022 | -$266.80M | – |
| Q3 FY2021CQ4 2021 | Dec 31, 2021 | -$246.02M | – |
| Q2 FY2021CQ3 2021 | Sep 30, 2021 | -$684.43M | – |
| Q1 FY2021CQ2 2021 | Jun 30, 2021 | -$154.39M | – |
| Q4 FY2020CQ1 2021 | Mar 31, 2021 | -$540.83M | – |
| Q3 FY2020CQ4 2020 | Dec 31, 2020 | -$259.07M | – |
| Q2 FY2020CQ3 2020 | Sep 30, 2020 | -$156.54M | – |
| Q1 FY2020CQ2 2020 | Jun 30, 2020 | -$114.45M | – |
See a number that looks wrong?